Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 100kWORD 16k
30 September 2016
E-007386-16
Question for written answer E-007386-16
to the Commission
Rule 130
Miriam Dalli (S&D)

 Subject:  Antimicrobial resistance action
 Answer in writing 

In 2011, the EU adopted an action plan to counter rising threats from antimicrobial resistance. This plan will expire in November.

Medical experts predict that drug-resistant infections could result in 10 million deaths worldwide per annum by the year 2050. An additional preoccupation in the EU is that knowledge about antimicrobial resistance (AMR) remains low.

Two health interest groups, the European Public Health Alliance and the European Federation of Pharmaceutical Industries and Association have commented that the State of the European Union speech did not give enough attention to Europe’s role in protecting and improving Europeans’ health.

— When does the Commission intend to publish the follow-up to the 2011 European Action Plan against AMR?— How does the EU intend to take measures and address the AMR challenge?— In other global issues the EU has taken a world leadership role; does it anticipate to act similarly in the case of AMR prevention?

Legal notice